Allow me to break it down! This is what most will see tomorrow! Well the broad strokes anyways! Hehehe
$Macrogenics (MGNX.US)$ Financial Performance:
MacroGenics reported a significant increase in Q2 2024 revenue of $110.7 million, compared to $10.4 million in the same quarter the previous year.
Net income for the quarter was $56.3 million, significantly higher than the $17.6 million recorded in Q3 2023.
The financial improvements were largely due to a $100 million milestone payment from Incyte, and the company's cash balance at the end of the quarter was $200.4 million.
MacroGenics reported a significant increase in Q2 2024 revenue of $110.7 million, compared to $10.4 million in the same quarter the previous year.
Net income for the quarter was $56.3 million, significantly higher than the $17.6 million recorded in Q3 2023.
The financial improvements were largely due to a $100 million milestone payment from Incyte, and the company's cash balance at the end of the quarter was $200.4 million.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Lnova :
Lnova : good job $Macrogenics (MGNX.US)$
Trytosaveabit OP Lnova : Plus expected to receive another 40 million payment before EOY
Lnova Trytosaveabit OP : wow watching
Lnova : The turnover looks 4x the volume. It is shorted ?
DDDDDDDDDDD : look at $Nature's Miracle (NMHI.US)$ and $Bluejay Diagnostics (BJDX.US)$
Trytosaveabit OP Lnova : Yes it is over 10% SI
Trytosaveabit OP DDDDDDDDDDD : Yup! NMHI needs volume